Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2006

View Archived Issues

Tanabe Seiyaku updates pipeline status

Angiostatin, endostatin and saxatilin gene cotransfection blocks tumor growth in vivo

Durect reveals intended milestones for 2006

New phase II trial investigates bicifadine for osteoarthritis

Targeting the Sonic hedgehog pathway for CNS pathology in Down's syndrome

Nabi vaccines stimulate antibody responses in phase I trials

Australian centers to study new therapeutics vaccine for genital warts

New inhibitory peptide targets SARS-CoV spike protein to block infectivity

Elan to sell European Prialt rights to Eisai

DOR preparing regulatory submissions for orBec in iGVHD

Ceragenix enters CRADA with CDC to evaluate Ceracide in biofilm prevention

Zonagen seeks stockholder approval to change name to Repros Therapeutics

Igeneon and Celltrion sign letter of intent to amend IGN-311 agreement

ALGRX-4975 completes postsurgery phase II studies

MERLIN study of Ranexa cleared to continue

Genzyme launches test to monitor Gleevec resistance

Results of INFUSE-LR study of Hylenex

NeoPharm updates progress of LEP-ETU

Medivir designates candidate drug from HIV NNRTI program

New potent and selective HCV polymerase inhibitors are effective against multiple genotypes

Ras plays an important tumorgenic role in the liver

Recent GSK patents report new treatments for psychotic disorders

New therapeutics for cancer covered in recent patent literature

Rituxan approved with CHOP for diffuse large B-cell NHL

New data presented on PEDF gene therapy for age-related macular degeneration / News in Context

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...